ÂÜÀòÂÒÂ×

Dr. Gregory Zarbis-Papastoitsis is the EVP of Process and Manufacturing Sciences at Ankyra, where he is responsible for all CMC and related regulatory activities. Prior to joining Ankyra, Dr. Papastoitsis was the EVP of Process and Manufacturing at Compass Therapeutics where he oversaw all CMC activities for a CD137 agonist, which is currently in Phase 1 clinical studies. Previously he was the SVP of development and manufacturing at Eleven Biotherapeutics. There, he worked on an IL-1 inhibitor, which reached pivotal clinical studies for Dry Eye Disease and Allergic Conjunctivitis, and an anti-IL6 antibody (successfully filed an IND), for treating Macular Edema. Prior to Eleven, he was the Senior Director of Purification and Analytical Development at PERCIVIA, LLC, developing platform processes with the PER.C6® human cell line. Previously, he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, where he was responsible for the early clinical development of a long-lasting Factor IX (ALPROLIX®).

Before Syntonix, Dr. Zarbis-Papastoitsis worked on the commercial manufacturing process of HUMIRA® (Abbott/Abbvie), and on the purification process of ONTAK®, an IL2-diphtheria toxin fusion protein (Seragen). Prior to that, at Millennium Pharmaceuticals, he was responsible for the early development of an antibody-toxin conjugate (anti-PSMA-DM1) that reached Phase I clinical trials for prostate cancer and was a key contributor in the process development of an anti-CCR2 antibody that was in Phase II clinical trials for autoimmune diseases. He received his Ph.D. in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer's disease.